Cross-border paid plasma donation among injection drug users in two Mexico–U.S. border cities-Reference-Cited by-同舟云学术

Cross-border paid plasma donation among injection drug users in two Mexico–U.S. border cities

Published:2009-09 Issue:5 Volume:20 Page:409-412
ISSN:0955-3959
Container-title:International Journal of Drug Policy
language:en
Short-container-title:International Journal of Drug Policy

Author:

Volkow Patricia,Brouwer Kimberly C.,Loza Oralia,Ramos Rebeca,Lozada Remedios,Garfein Richard S.,Magis-Rodriguez Carlos,Firestone-Cruz Michelle,Strathdee Steffanie A.

Publisher

Elsevier BV

Subject

Health Policy,Medicine (miscellaneous)

Reference32 articles.

1. Paid blood donors: a new risk group for the development of AIDS in Mexico;Alvarez-Suarez;Salud Publica De Mexico,1989

2. Outbreak of hepatitis C associated with intravenous immunoglobulin administration—United States, October 1993–June 1994;Anonymous;MMWR,1994

3. The epidemiology of HIV transmission among paid plasma donors, Mexico City, Mexico;Avila;AIDS,1989

4. Parvovirus B19 transmission by heat-treated clotting factor concentrates;Blumel;Transfusion,2002

5. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study;Bresee;JAMA,1996

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update on Viral Hepatitis B and C in Mexico: Advances and Pitfalls in Eradication Strategies;Microorganisms;2024-07-03

2. Hepatitis C Among People Who Inject Drugs (PWID) in Latin America and the Caribbean: A Meta-Analysis of Prevalence Over Three Decades;Journal of Studies on Alcohol and Drugs;2023-01

3. Bloody Bioethics;ROUTL ANN BIOETHICS;2022-01-06

4. A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico—A systematic review and meta-analysis (2008–2019);Annals of Hepatology;2021-01

5. Factors associated with syphilis seroreactivity among polydrug users in Northeast Brazil: A cross-sectional study using Respondent Driven Sampling;International Journal of Drug Policy;2017-01